Stock Track | Novo Nordisk Soars 5.01% Intraday on Positive Pediatric Trial Results and Strong Oral Drug Performance

Stock Track

Apr 24

Novo Nordisk A/S (NVO) shares surged 5.01% during intraday trading on Friday, marking a significant upward movement for the pharmaceutical stock.

The sharp rise is attributed to two key positive developments. First, the company announced positive late-stage clinical trial results for its oral semaglutide in children and adolescents with type 2 diabetes. The PIONEER TEENS trial met its primary endpoint, demonstrating a statistically significant reduction in blood sugar levels, with plans to file for regulatory approval for this new patient population later in the year.

Secondly, the stock gained strength from data showing Novo Nordisk's oral Wegovy pill is significantly outperforming rival Eli Lilly's newly launched oral weight-loss drug, Foundayo, in early prescription numbers. This performance reinforces Novo Nordisk's competitive lead in the crucial oral anti-obesity and diabetes drug market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1183373580"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183373580\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183373580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183373580","market":"sg","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Soars 5.01% Intraday on Positive Pediatric Trial Results and Strong Oral Drug Performance","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) shares surged 5.01% during intraday trading on Friday, marking a significant upward movement for the pharmaceutical stock.</p><p>The sharp rise is attributed to two key positive developments. First, the company announced positive late-stage clinical trial results for its oral semaglutide in children and adolescents with type 2 diabetes. The PIONEER TEENS trial met its primary endpoint, demonstrating a statistically significant reduction in blood sugar levels, with plans to file for regulatory approval for this new patient population later in the year.</p><p>Secondly, the stock gained strength from data showing Novo Nordisk's oral Wegovy pill is significantly outperforming rival Eli Lilly's newly launched oral weight-loss drug, Foundayo, in early prescription numbers. This performance reinforces Novo Nordisk's competitive lead in the crucial oral anti-obesity and diabetes drug market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Soars 5.01% Intraday on Positive Pediatric Trial Results and Strong Oral Drug Performance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Soars 5.01% Intraday on Positive Pediatric Trial Results and Strong Oral Drug Performance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-24 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) shares surged 5.01% during intraday trading on Friday, marking a significant upward movement for the pharmaceutical stock.</p><p>The sharp rise is attributed to two key positive developments. First, the company announced positive late-stage clinical trial results for its oral semaglutide in children and adolescents with type 2 diabetes. The PIONEER TEENS trial met its primary endpoint, demonstrating a statistically significant reduction in blood sugar levels, with plans to file for regulatory approval for this new patient population later in the year.</p><p>Secondly, the stock gained strength from data showing Novo Nordisk's oral Wegovy pill is significantly outperforming rival Eli Lilly's newly launched oral weight-loss drug, Foundayo, in early prescription numbers. This performance reinforces Novo Nordisk's competitive lead in the crucial oral anti-obesity and diabetes drug market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1183373580","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183373580","pubTimestamp":1777039066,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S (NVO) shares surged 5.01% during intraday trading on Friday, marking a significant upward movement for the pharmaceutical stock.The sharp rise is attributed to two key positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"股票赛道|诺和诺德盘中大涨5.01%，儿科试验结果积极，口服药表现强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) shares surged 5.01% during intraday trading on Friday, marking a significant upward movement for the pharmaceutical stock.The sharp rise is attributed to two key positive developments. First, the company announced positive late-stage clinical trial results for its oral semaglutide in children and adolescents with type 2 diabetes. The PIONEER TEENS trial met its primary endpoint, demonstrating a statistically significant reduction in blood sugar levels, with plans to file for regulatory approval for this new patient population later in the year.Secondly, the stock gained strength from data showing Novo Nordisk's oral Wegovy pill is significantly outperforming rival Eli Lilly's newly launched oral weight-loss drug, Foundayo, in early prescription numbers. This performance reinforces Novo Nordisk's competitive lead in the crucial oral anti-obesity and diabetes drug market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}